Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|S1011||SWOG||A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|A041501||Alliance||A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL||Adult CIRB - Late Phase Emphasis||Available to Open|
|WF-97415||NCORP-Wake Forest University||Understanding and Predicting Breast Cancer Events after Treatment (UPBEAT)||Cancer Prevention and Control CIRB||Available to Open|
|ADVL18P1||COG||An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML) with an Isocitrate Dehydrogenase-2 (IDH2) Mutation||Pediatric CIRB||Available to Open|
|10346||ETCTN||Pilot Study of DS-8201a Pharmacodynamics in Patients with HER2-expressing Advanced Solid Tumors||Adult CIRB - Early Phase Emphasis||Available to Open|
|E2108||ECOG||A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA6134||ECOG-ACRIN||A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|ALTE05N1||COG||Umbrella Long-Term Follow-Up Protocol||Pediatric CIRB||Available to Open|
|AGCT1532||COG||Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotheraphy for patients with intermediate and poor-risk metastatic germ cell tumours||Pediatric CIRB||Available to Open|
|ANBL17P1||COG||A Pilot Induction Regimen Incorporating Chimeric 14.18 Antibody (ch14.18, dinutuximab) (NSC# 764038, IND# 4308) and Sargramostim (GM-CSF) for the Treatment of Newly Diagnosed High-Risk Neuroblastoma||Pediatric CIRB||Available to Open|